For example, galantamine, a Food and Drug Administration-approved medication for the treatment of cognitive deficits associated with Alzheimer’s disease, increases synaptic acetylcholine levels by inhibiting acetylcholinesterase, an enzyme that breaks down acetylcholine. The gene discussed is ACHE; the disease is early-onset autosomal dominant Alzheimer disease.